Interpretation of the latest price and medical insurance policy of Regorafenib in 2025

Regorafenib (Regorafenib) is an oral multi-target tyrosine kinase inhibitor that has been officially launched in China and has been included in the national medical insurance directory, providing patients with better accessibility. The latest prices in 2025 show that the domestic market price of regorafenib is about four to five thousand yuan. Since it has entered the scope of medical insurance, the patient's out-of-pocket proportion after medical insurance reimbursement will be significantly reduced, greatly reducing the financial burden. However, the specific reimbursement ratio will vary depending on regional policies. It is recommended that patients consult the local medical insurance department or hospital pharmacy to obtain accurate cost information before taking medication.

In the foreign market, the original drug of regorafenib mainly comes from Türkiye. Its price is about more than 1,000 yuan, which has a certain price advantage compared with the domestic price. In the field of generic drugs, countries such as India, Bangladesh, and Laos have launched generic versions, with prices generally ranging from a few hundred yuan to more than a thousand yuan. The ingredients of these generic drugs are basically the same as those of the original drugs, and the clinical efficacy is relatively reliable. Therefore, they have become a cost-effective choice for patients who need to take medicine for a long time.

The coverage of medical insurance policies is a key to the promotion of regorafenib in China. As an important drug for the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma, the inclusion in medical insurance allows more patients to adhere to the medication for a long time and improves the overall treatment effect. Different regions may have differences in reimbursement ratios, deductibles, and maximum payment limits. Therefore, patients need to make a reasonable medication plan based on their personal medical insurance conditions. Some cities will also provide secondary subsidies for patients with severe or rare cancers to further reduce family financial pressure.

In general, the price and medical insurance policy of regorafenib in2025 reflect the balance between "clinical needs and patient affordability". Domestic patients can obtain medicines at lower costs through medical insurance channels, and they also have the flexibility to choose original drugs or generic drugs through overseas channels. In the future, with the continuous optimization of medical insurance payment methods and the expansion of the generic drug market, the accessibility of regorafenib is expected to further increase, allowing more patients to benefit from this targeted treatment.

Reference link:https://www.drugs.com